Canada’s SaNOtize develops anti-viral nasal spray with efficacy to reduce 95% viral load in 24 hours

Canada’s SaNOtize develops anti-viral nasal spray with efficacy to reduce 95% viral load in 24 hours

An anti-viral nasal spray, branded as Enovid that was developed by a research-based Canadian pharmaceutical company SaNOtize Research and Development Corp., and recently tested in the UK, can reportedly reduce the viral loads in confirmed COVID-19 cases by 95% in 24 hours and 99% in 72 hours.  The spray employs nitric oxide as a mechanical and chemical barrier against viral infection in the nose, which is where respiratory diseases like COVID-19 infiltrate the body.

The spray, currently manufactured in Israel, can be used up to five times a day after coming in contact with viruses, according to a media release from the company. It is suitable for children as young as 12 years old, and the Ministry of Health had approved it for trials in January this year. The spray will go on sale in the coming week,  The Jerusalem Post reported on Sunday quoting the press release.

“The spray we developed has been proven not only as a virus blocker that causes Covid-19 but also as a killer,” said Dr. Gili Regev, CEO and Founder of SaNOtize.  Since most COVID-19 infections are nasal, SaNOtize believes this is an effective way to reduce the spread and infection of COVID-19. It has been able to suppress the SARS-CoV-2 virus within two minutes, including the Alpha and Gamma variants, according to the release. It is currently being tested against the Delta variant. According to the company release, the spray is also effective against other respiratory viruses such as those that cause flu.